• 1
    Raisz LG 1997 The osteoporosis revolution. Ann Intern Med 126:458462.
  • 2
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:15891593.
  • 3
    Fujisaki J, Tokunaga Y, Takahashi T, Hirose T, Shimojo F, Kagayama A, Hata T 1995 Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: Synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 3:273282.
  • 4
    Bauss F, Esswein A, Reiff K, Sponer G, Muller-Beckmann B 1996 17b-Estaradiol-bisphosponate conjugates (E2-BPs): Pontential bone-seeking estrogen-products; serum kinetic and in vivo effects on bone mass in ovariectomized rats. J Bone Miner Res 10(Suppl 1):S251.
  • 5
    Harada H, Tsushima N, Katsumata T, Nakatsuka M 1997 Bone-selective bisphosphonate-estrogen hybrid compound, SM-16896, acts as estrogen in the bone. J Bone Miner Res 12(Suppl 1):S472.
  • 6
    Kamizono A, Yamamoto A, Minegishi T, Mori Y, Tsuchiya T, Ueno H, Nakao Y, Kadowaki S 1997 MCC-565, a novel bone selective 17 beta-estradiol-bisphosphonate conjugate, prevents bone Loss with much reduced systemic effects in ovariectomized aged rats. J Bone Miner Res 12(Suppl 1):S472.
  • 7
    Fujisaki J, Tokunaga Y, Takahashi T, Shimojo F, Kimura S, Hata T 1998 Osteotropic drug delivery system based on bisphosphonic prodrug-IV—effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J Drug Target 5:129138.
  • 8
    Butler WT 1989 The nature and significance of osteopontin. Connect Tissue Res 23:123136.
  • 9
    Oldberg A, Franzen A, Heinegard D 1986 Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 83:88198823.
  • 10
    Oldberg A, Franzen A, Heinegard D 1988 The primary structure of a cell-binding bone sialoprotein. J Biol Chem 263:1943019432.
  • 11
    Nagata T, Bellows CG, Kasugai S, Butler WT, Sodek J 1991 Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem J 274(Pt 2):513520.
  • 12
    Kasugai S, Todescan R Jr., Nagata T, Yao KL, Butler WT, Sodek J 1991 Expression of bone matrix proteins associated with mineralized tissue formation by adult rat bone marrow cells in vitro: Inductive effects of dexamethasone on the osteoblastic phenotype. J Cell Physiol 147:111120.
  • 13
    Kasugai S, Nagata T, Sodek J 1992 Temporal studies on the tissue compartmentalization of bone sialoprotein (BSP), osteopontin (OPN), and SPARC protein during bone formation in vitro. J Cell Physiol 152:467477.
  • 14
    Fujisawa R, Kuboki Y 1991 Preferential adsorption of dentin and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta 1075:5660.
  • 15
    Fujisawa R, Wada Y, Nodasaka Y, Kuboki Y 1996 Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals. Biochim Biophys Acta 1292:5360.
  • 16
    Merrifield RB 1963 Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85:21492154.
  • 17
    Maeda H, Ishida N, Kawauchi H, Tsujimura K 1969 Reaction of fluorescein-isothiocyanate with proteins and amino acids. I. Covalent and non-covalent binding of fluorescein-isothiocyanate and fluorescein to proteins. J Biochem 65:777783.
  • 18
    Tonna EA, Singh IJ, Shu HS 1984 Non-radioactive tracer techniques for calcified tissues. In: DicksonGR (ed.) Methods of Calcified Tissue Preparation. Elsevier, Amsterdam, The Netherls, pp. 333368.
  • 19
    Jung A, Bisaz S, Fleisch H 1973 The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269280.
  • 20
    Fleisch H 1997 Bisphosphonates in Bone Disease from the Labortory to the Patient, 3rd Ed. The Parthenon Publishing Group, New York, NY, U.S.A., pp. 164180.
  • 21
    Bisaz S, Jung A, Fleisch H 1978 Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 54:265272.
  • 22
    Pongchaidecha M, Daley-Yates PT 1993 Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats. Drug Metab Dispos 21:100104.
  • 23
    Lin JH 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:7585.
  • 24
    Fujisaki J, Tokunaga Y, Sawamoto T, Takahashi T, Kimura S, Shimojo F, Hata T 1996 Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: Pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 4:117123.
  • 25
    Hosain F, Spencer RP, Couthon HM, Sturtz GL 1996 Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 37:105107.
  • 26
    Pasqualini R, Ruoslahti E 1996 Organ targeting in vivo using phage display libraries. Nature 380:364366.
  • 27
    Arap W, Pasqualini R, Ruoslahti E 1998 Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377380.
  • 28
    Cecchini MG, Ball R, Gautschi E, Miescher S, Wetterwald A, Zimmermann R, Stadler B 1997 Identification of a bone marrow endothelium homing peptide by phage peptide library panning in vivo. J Bone Miner Res 12(Suppl 1):S115.
  • 29
    Franzen A, Heinegard D 1985 Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232:715724.
  • 30
    Fisher LW, Hawkins GR, Tuross N, Termine JD 1987 Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem 262:97029708.
  • 31
    Zhang Q, Domenicucci C, Goldberg HA, Wrana JL, Sodek J 1990 Characterization of fetal porcine bone sialoproteins, secreted phosphoprotein I (SPPI, osteopontin), bone sialoprotein, and a 23-kDa glycoprotein. Demonstration that the 23-kDa glycoprotein is derived from the carboxyl terminus of SPPI. J Biol Chem 265:75837589.
  • 32
    Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S, Mizoguchi J, Kato K 1993 In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9:7380.
  • 33
    Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, Fukumoto S, Matsumoto T 1995 Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136:12761284.
  • 34
    Bagi CM, DeLeon E, Brommage R, Rosen D, Sommer A 1995 Treatment of ovariectomized rats with the complex of rhIGF-I/IGFBP-3 increases cortical and cancellous bone mass and improves structure in the femoral neck. Calcif Tissue Int 57:4046.
  • 35
    Bagi CM, DeLeon E, Brommage R, Adams S, Rosen D, Sommer A 1995 Systemic administration of rhIGF-I or rhIGF-I/IGFBP-3 increases cortical bone and lean body mass in ovariectomized rats. Bone 16(4 Suppl):263S269S.
  • 36
    Rosen D, Miller SC, DeLeon E, Thompson AY, Bentz H, Mathews M, Adams S 1994 Systemic administration of recombinant transforming growth factor beta 2 (rTGF-beta 2) stimulates parameters of cancellous bone formation in juvenile and adult rats. Bone 15:355359.
  • 37
    Machwate M, Zerath E, Holy X, Hott M, Godet D, Lomri A, Marie PJ 1995 Systemic administration of transforming growth factor-beta 2 prevents the impaired bone formation and osteopenia induced by unloading in rats. J Clin Invest 96:12451253.
  • 38
    Kasugai S, Waki Y, Miyamoto K, Fujisawa R, Kondo H, Kuroda S, Ohya K 1999 Selective effect of (Asp)6-estradiol on bone in ovariectomized mice. J Bone Miner Res 14(Suppl 1):S534.